Quality Management Section
A Quality Management section explains the trial-level approach for building quality into design and conduct, identifying critical-to-quality factors, and managing material risks. It is broader than sponsor monitoring and distinct from database-focused Data Management.
A Quality Management section describes how quality is built into the trial, which factors are critical to quality, and how important risks are identified, controlled, reviewed, and escalated.
Key details
Important caveats
Scope Boundary
Do not equate quality management with monitoring alone or with data cleaning alone. The approach should be proportionate to the trial and scoped to applicable sponsor/regulatory requirements.
Further guidance
Content
Describe critical-to-quality factors, risk identification/evaluation, proportionate controls, communication/escalation, review of emerging issues, and how important quality decisions are documented.
Purpose
Connect quality planning to participant protection and reliable trial results rather than treating quality as an end-stage inspection exercise.
Sources and evidence
Sources are shown with the role they play in this guide. Historical or style-sensitive claims are kept within the evidence boundary described above.
- E6(R3) Good Clinical Practice Guidance for Industry — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current ICH E6(R3) GCP guidance on investigator oversight, training/delegation, participant withdrawal, investigational-product accountability, site close-out, essential records, and insurance/indemnification
- E6(R3) Good Clinical Practice (GCP) — September 2025 (opens in a new tab)U.S. Food and Drug Administration · Current FDA final-guidance overview for ICH E6(R3), including quality by design, risk-based quality management, technology, proportionality, and clarified sponsor/investigator responsibilities